ATS Co. (TSE:ATS – Free Report) – Equities researchers at Raymond James dropped their Q2 2025 earnings per share (EPS) estimates for shares of ATS in a research report issued to clients and investors on Thursday, September 19th. Raymond James analyst M. Glen now forecasts that the company will post earnings of $0.37 per share for the quarter, down from their previous forecast of $0.38. The consensus estimate for ATS’s current full-year earnings is $2.14 per share. Raymond James also issued estimates for ATS’s Q3 2025 earnings at $0.47 EPS and FY2025 earnings at $1.94 EPS.
ATS (TSE:ATS – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported C$0.50 EPS for the quarter, missing analysts’ consensus estimates of C$0.53 by C($0.03). ATS had a return on equity of 11.30% and a net margin of 6.10%. The business had revenue of C$694.30 million for the quarter, compared to analyst estimates of C$689.19 million.
View Our Latest Stock Report on ATS
ATS Stock Performance
ATS stock opened at C$39.89 on Monday. ATS has a 52 week low of C$33.47 and a 52 week high of C$60.15. The stock has a market capitalization of C$3.88 billion, a P/E ratio of 21.80 and a beta of 1.35. The stock has a fifty day moving average of C$38.35 and a 200-day moving average of C$42.66.
ATS Company Profile
ATS Corporation, together with its subsidiaries, provides automation solutions worldwide. The company is also involved in planning, designing, building, commissioning, and servicing automated manufacturing and assembly systems, including automation products and test solutions. In addition, it offers pre-automation services comprising discovery and analysis, concept development, simulation, and total cost of ownership modelling; post automation services, including training, process optimization, preventative maintenance, emergency and on-call support, spare parts, retooling, retrofits, and equipment relocation; and contract manufacturing services, as well as after sales and services.
Further Reading
- Five stocks we like better than ATS
- What are earnings reports?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What is Forex and How Does it Work?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Using the MarketBeat Stock Split Calculator
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for ATS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ATS and related companies with MarketBeat.com's FREE daily email newsletter.